Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Three studies show ACP-104 safe, well tolerated, with initial antipsychotic effect

July 18, 2006

ReGen and Metagenics enter commercialization agreement for Colostrinin

July 18, 2006

CNI-1493 facilitates dramatic reductions in Abeta and microglial activity in AD

July 17, 2006

Novel antibody-independent nasal vaccination for AD

July 17, 2006

Oral Posiphen markedly attenuates Abeta-42 in vivo

July 17, 2006

Neuroprotective action of minocycline associated to PARP-1 inhibition

July 17, 2006

RAID Pilot Program supports development of EPI-A0001 for Friedreich's ataxia

July 17, 2006

Fentanyl Taifun shows efficacy in breakthrough cancer pain

July 17, 2006

Novel agents for neurodegenerative diseases and nausea revealed

July 14, 2006

Anesiva plans NDA filing for 3268

July 14, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...